sodium;(4S)-5-hydroxy-5-oxo-4-[(2-phenylacetyl)amino]pentanimidate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: sodium;(4S)-5-hydroxy-5-oxo-4-[(2-phenylacetyl)amino]pentanimidate
• 化学式: C13H15N2NaO4
• 分子量: 286.26
• InChiKey: JABIYIZXMBIFLT-PPHPATTJSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -4.27
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  112
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
  申请人：——

  公开号：US20010044466A1

  公开（公告）日：2001-11-22

  Herein is disclosed a method of treating neoplastic disease, including cancer, comprising administering a pharmaceutical composition, the pharmaceutical composition comprising a highly concentrated aqueous solution of phenylacetylglutamine and phenylacetylisoglutamine in a 4:1 ratio, at an infusion rate of from 100 mL/hr to 400 mL/hr. In a further embodiment, herein is also disclosed a method of treating neoplastic disease, including cancer, comprising administering a pharmaceutical composition, the pharmaceutical composition comprising a highly concentrated aqueous solution of phenylacetate and (phenylacetylglutamine or phenylacetylisoglutamine) in a 4:1 ratio, at an infusion rate of from 100 mL/hr to 400 mL/hr. Herein are also disclosed the pharmaceutical compositions used in the above methods.

  本文披露了一种治疗恶性肿瘤疾病，包括癌症的方法，该方法包括给予一种药物组合物，该药物组合物包括苯乙酰谷氨酰胺和苯乙酰异谷氨酰胺的高浓度水溶液，比例为4：1，输注速率为100毫升/小时至400毫升/小时。在另一种实施方式中，本文还披露了一种治疗恶性肿瘤疾病，包括癌症的方法，该方法包括给予一种药物组合物，该药物组合物包括苯乙酸和（苯乙酰谷氨酰胺或苯乙酰异谷氨酰胺）的高浓度水溶液，比例为4：1，输注速率为100毫升/小时至400毫升/小时。本文还披露了上述方法中使用的药物组合物。
• Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis
  申请人：BURZYNSKI, Stanislaw R.

  公开号：EP0680756A1

  公开（公告）日：1995-11-08

  The present invention provides methods for treating neurofibromatosis in humans by administering to an afflicted host pharmaceutical compositions containing a therapeutically effective amount of a combination of in a weight ratio ranging from about 1:1 to about 1:10 (A:B); wherein R is OH, NH₂, OW, or H; X is H, F, Cl, Br, I, OH, OW, NO₂ or NH₂; Y is H, F, Cl, Br, or I; W is or a C₁ to C₂ aliphatic group; Z is an aliphatic or aromatic group of C₁ to C₁₂; X and Y can both vary within the compound; or pharmaceutically acceptable salts thereof. Particularly disclosed herein is a composition comprising a 1:4 ratio of the sodium salts of phenylacetylglutamine and phenylacetic acid, formulated in both oral and parenteral forms. Typically, the patient is given the combination composition from 1 to 20g/day in divided doses. After several months of treatment patients exhibit significant decrease in number and size of nodules.

  本发明提供了治疗人类神经纤维瘤病的方法，其方法是向患病宿主施用药物组合物，该药物组合物含有治疗有效量的以下物质的组合 重量比范围为约 1:1 至约 1:10 (A:B)； 其中 R 是 OH、NH₂、OW 或 H； X 是 H、F、Cl、Br、I、OH、OW、NO₂ 或 NH₂； Y 是 H、F、Cl、Br 或 I； W 是 或 C₁ 至 C₂ 脂肪族基团； Z 是 C₁ 至 C₁₂ 脂肪族或芳香族基团； X 和 Y 可在化合物中同时变化；或 其药学上可接受的盐类。 本文特别公开了一种组合物，它由苯乙酰谷氨酰胺钠盐和苯乙酸钠盐按 1:4 的比例配制而成，既有口服形式，也有肠外形式。通常情况下，患者每天分次服用 1 至 20 克的组合物。经过几个月的治疗后，患者的结节数量和大小都会明显减少。
• Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives
  申请人：Burzynski R. Stanislaw

  公开号：US20060205818A1

  公开（公告）日：2006-09-14

  Provided are methods of treating von Hippel-Lindau disease (VHL). Specifically embodiments of the invention provide methods for the treatment of a patient afflicted with VHL using phenylacetyl-derivatives. Preferred embodiments of the invention provide for the use of phenylacetic acid (or its sodium salt), phenylacetylglutamine (or its sodium salt) and/or phenylacetylisoglutamine (or its sodium salt) to treat VHL. Other embodiments of the invention provide for the use of phenylacetyl-derivatives for the manufacture of a medicament for the treatment of VHL.

  本发明提供了治疗von Hippel-Lindau病（VHL）的方法。具体而言，本发明的实施方案提供了使用苯乙酰基衍生物治疗VHL患者的方法。本发明的优选实施方案提供了使用苯乙酸（或其钠盐）、苯乙酰基谷氨酰胺（或其钠盐）和/或苯乙酰基异谷氨酰胺（或其钠盐）治疗VHL的方法。本发明的其他实施方案提供了苯乙酰基衍生物用于制造治疗 VHL 的药物。
• Pharmaceutical composition comprising phenyl acetyl glutamine,a combination of this compound with phenylacetic acid or 3-(phenylacetylamino)piperidine-2,6-dione,a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino)piperidine-2,6-dione
  申请人：BURZYNSKI, Stanislaw R.

  公开号：EP0069232B1

  公开（公告）日：1986-10-29
• PHARMACEUTICAL COMPOSITIONS FOR USE IN TREATING AIDS
  申请人：BURZYNSKI, Stanislaw R.

  公开号：EP0500905A1

  公开（公告）日：1992-09-02